# Wegovy (semaglutide): Dosage, Side Effects & Uses | PepVault

Source: https://pepvault.app/drugs/wegovy

Last updated: 2026-11-18

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Brand-name drugs](https://pepvault.app/drugs) Wegovy

Brand-name drug · GLP-1 receptor agonist

# Wegovy (semaglutide)

From the FDA label, read Nov 18, 2026 [Published by PepVault](https://pepvault.app/guides/how-we-research)

Wegovy is a prescription medicine from Novo Nordisk with semaglutide as its active ingredient, made as a weekly injection and as a daily tablet.

FDA approved it, alongside a lower-calorie diet and more activity, to reduce excess weight and keep it off in adults with obesity or overweight with a weight-related condition, and to lower the risk of heart attack, stroke and heart-related death in adults with heart disease and obesity or overweight.

- **Active ingredient:** [Semaglutide](https://pepvault.app/peptides/semaglutide), [Semaglutide (oral)](https://pepvault.app/peptides/semaglutide-oral)
- **Maker:** Novo Nordisk
- **Class:** GLP-1 receptor agonist
- **FDA application:** [NDA 215256](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256), first approved 2021

## What FDA approved it for

The injection is also approved for children 12 and older with obesity, and for adults with a liver disease called MASH (once known as NASH) with moderate to advanced scarring. The MASH use is an accelerated approval: it rests on liver biopsies improving, and staying approved may depend on a confirming trial.

The tablets carry the two adult uses, weight and heart risk, and are not approved for children or for MASH. The label advises against using Wegovy with any other semaglutide product or another GLP-1 medicine.

From the label: 1 Indications and Usage.

## How it is supplied

Wegovy’s forms and the doses each one gives, as the label lists them

| Form | Doses |
| --- | --- |
| Single-dose pen | 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, 7.2 mg (Wegovy HD) |
| Single-dose syringe | 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg |
| FlexTouch pen (4 weekly doses) | 2.4 mg |
| Tablet | 1.5 mg, 4 mg, 9 mg, 25 mg |

From the label: 3 Dosage Forms and Strengths.

## The label’s dosing schedule

This is the dosing schedule as the FDA label states it. A prescriber sets the actual dose and when it changes; it is not an instruction to the reader.

### Wegovy injection, once a week

Wegovy’s steps as the label lays them out, lowest to highest; each bar’s height is its dose against the top dose. A dashed bar is a step the label allows only if more is needed.

Wegovy injection, once a week: the steps on the label. Highest dose: 7.2 mg a week.

| Dose | When, on the label |
| --- | --- |
| 0.25 mg a week | Weeks 1 to 4 |
| 0.5 mg a week | Weeks 5 to 8 |
| 1 mg a week | Weeks 9 to 12 |
| 1.7 mg a week | Weeks 13 to 16 |
| 2.4 mg a week | From week 17 (maintenance) |
| 7.2 mg a week | Adults, after at least 4 weeks on 2.4 mg, if needed |

The label lists 2.4 mg as the recommended lasting dose for weight, with 1.7 mg as the other option; 7.2 mg is the top dose for adults and comes as Wegovy HD. Children 12 and older stay at 2.4 mg or 1.7 mg.

If a step is hard to tolerate, the label suggests waiting 4 more weeks before the next one.

### Wegovy tablets, once a day

Wegovy’s steps as the label lays them out, lowest to highest; each bar’s height is its dose against the top dose. A dashed bar is a step the label allows only if more is needed.

Wegovy tablets, once a day: the steps on the label. Highest dose: 25 mg a day.

| Dose | When, on the label |
| --- | --- |
| 1.5 mg a day | Days 1 to 30 |
| 4 mg a day | Days 31 to 60 |
| 9 mg a day | Days 61 to 90 |
| 25 mg a day | From day 91 (maintenance) |

The tablets climb over three months to a lasting dose of 25 mg a day. A person who can’t tolerate 25 mg may be moved to the 1.7 mg weekly injection instead.

Switching from the 2.4 mg injection, the 25 mg tablets start one week after the last shot; going the other way, the 2.4 mg injection starts the day after the last tablet.

From the label: 2.2 Recommended Dosage for WEGOVY Injection; 2.3 Recommended Dosage of WEGOVY Tablets; 2.5 Switching Between WEGOVY Injection and WEGOVY Tablets.

## How it’s taken

The injection is given once a week on the same weekday, at any hour and with or without a meal, under the skin of the belly, thigh or upper arm, rotating the spot each time. Wegovy comes in single-dose pens and syringes and in a FlexTouch pen holding four weekly doses.

A Wegovy tablet is taken each morning before eating, swallowed whole with no more than 4 ounces of water, then nothing else by mouth for at least 30 minutes.

From the label: 2.1 Important Monitoring and Administration Instructions.

<!--promo-->

PepVault for iPhone

## Keep your own record in PepVault

Log each dose on your schedule, with a reminder for the next one.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=brand-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## If a dose is missed

For a missed injection, the label looks at the next scheduled dose: more than 2 days away, take the missed one as soon as possible; less than 2 days away, skip it. Missing 2 or more weeks in a row means starting the climb again from a lower dose.

A missed Wegovy tablet is simply skipped, with the next tablet the following day.

From the label: 2.4 Recommendations Regarding Missed Dose(s).

## Storage

Single-dose pens and syringes belong in the fridge at 36°F to 46°F, in their carton and away from light; before the cap comes off, one can wait up to 28 days at 46°F to 86°F. A FlexTouch pen in use keeps for 56 days at 59°F to 86°F or in the fridge.

The tablets are kept at 68°F to 77°F in their original bottle, which protects them from moisture.

From the label: 16 How Supplied/Storage and Handling.

## Side effects and warnings

Adverse reactions in at least 2% of adults on the Wegovy 2.4 mg injection and more often than on placebo, weight trials (first ten rows). Percent of people.

| Reaction | Placebo | 2.4 mg |
| --- | --- | --- |
| Nausea | 16 | 44 |
| Diarrhea | 16 | 30 |
| Vomiting | 6 | 24 |
| Constipation | 11 | 24 |
| Abdominal pain | 10 | 20 |
| Headache | 10 | 14 |
| Fatigue | 5 | 11 |
| Dyspepsia | 3 | 9 |
| Dizziness | 4 | 8 |
| Abdominal distension | 5 | 7 |

In those weight trials, 6.8% of adults on 2.4 mg stopped because of side effects, against 3.2% on placebo; nausea, vomiting and diarrhea were the usual reasons.

At 7.2 mg, nausea was reported by 39% and an odd skin sensation (tingling or burning, which the label calls dysesthesia) by 22%, against 6% at 2.4 mg.

### The boxed warning

**Boxed warning: “RISK OF THYROID C-CELL TUMORS”**Like the other semaglutide labels, Wegovy’s carries a boxed warning on the risk of thyroid C-cell tumors: semaglutide caused them in rodents, and the label says it is unknown whether it does in humans. People with medullary thyroid carcinoma in themselves or their family, or with MEN 2, should not use it.

### The other warnings

The warnings section also covers pancreatitis, gallbladder disease, low blood sugar, kidney injury from fluid loss, severe stomach side effects, allergic reactions, diabetic eye changes in type 2 diabetes, a faster heart rate and aspiration under anesthesia.

From the label: 6.1 Clinical Trials Experience; Boxed Warning; 5 Warnings and Precautions.

## How Wegovy differs from Ozempic and Rybelsus

Wegovy, Ozempic and Rybelsus hold the same active ingredient, semaglutide. What sets them apart is on their labels: what each is approved for, the forms it comes in and how high its schedule goes.

Semaglutide brands, label against label

| Compared | [Wegovy](https://pepvault.app/drugs/wegovy) | [Ozempic](https://pepvault.app/drugs/ozempic) | [Rybelsus](https://pepvault.app/drugs/rybelsus) |
| --- | --- | --- | --- |
| Approved for | Weight reduction; heart risk with obesity; MASH (injection) | Type 2 diabetes; heart and kidney risk in type 2 diabetes | Type 2 diabetes; heart risk in type 2 diabetes |
| Forms | Single-dose pen; Single-dose syringe; FlexTouch pen; Tablet | Multi-dose pen; Single-dose prefilled syringe; Tablet | Tablet |
| Label’s dose range | injection: 0.25 mg to 7.2 mg once a week; tablets: 1.5 mg to 25 mg once a day | injection: 0.25 mg to 2 mg once a week; tablets: 1.5 mg to 9 mg once a day | 3 mg to 14 mg once a day |
| Top dose | 7.2 mg a week; 25 mg a day | 2 mg a week; 9 mg a day | 14 mg a day |
| Maker | Novo Nordisk | Novo Nordisk | Novo Nordisk |

[Ozempic vs Wegovy: the two labels side by side](https://pepvault.app/drugs/compare/ozempic-vs-wegovy)

## What else we have on semaglutide

### Semaglutide on PepVault

- [Semaglutide in the peptide library](https://pepvault.app/peptides/semaglutide)
- [Semaglutide (oral) in the peptide library](https://pepvault.app/peptides/semaglutide-oral)
- [Semaglutide: half-life](https://pepvault.app/peptides/semaglutide/half-life)
- [Semaglutide: side effects](https://pepvault.app/peptides/semaglutide/side-effects)
- [Semaglutide: how long it takes to work](https://pepvault.app/peptides/semaglutide/how-long-to-work)
- [Semaglutide (oral): half-life](https://pepvault.app/peptides/semaglutide-oral/half-life)
- [Semaglutide (oral): side effects](https://pepvault.app/peptides/semaglutide-oral/side-effects)
- [Is Semaglutide legal? FDA, DEA and WADA status](https://pepvault.app/peptides/semaglutide/legal-status)
- [Is Semaglutide (oral) legal? FDA, DEA and WADA status](https://pepvault.app/peptides/semaglutide-oral/legal-status)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)
- [Semaglutide (oral) dose guide](https://pepvault.app/lab/dosage/semaglutide-oral)

### Free tools

- [GLP-1 titration calculator](https://pepvault.app/tools/glp1-titration-calculator)
- [Missed a GLP-1 dose?](https://pepvault.app/tools/missed-glp1-dose)
- [Peptide half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### The trials, in plain English

- [Semaglutide: 14.9% weight loss at 68 weeks in STEP 1](https://pepvault.app/research/semaglutide-step-1-2021)
- [Semaglutide STEP 4: -7.9% weight vs +6.9% after switch to placebo](https://pepvault.app/research/semaglutide-step-4-2021)
- [Semaglutide: 6.5% vs 8.0% had a major heart event in SELECT](https://pepvault.app/research/semaglutide-select-2023)
- [Semaglutide 7.2 mg: 18.7% weight loss at 72 weeks in STEP UP](https://pepvault.app/research/semaglutide-step-up-2025)
- [Semaglutide: MASH resolved in 62.9% vs 34.3% on placebo at 72 weeks](https://pepvault.app/research/semaglutide-sanyal-2025)
- [Semaglutide 25 mg pill: 13.6% weight loss at 64 weeks in OASIS 4](https://pepvault.app/research/semaglutide-oasis-4-2025)
- [Semaglutide: 35% lower lunch energy intake vs placebo at 20 weeks](https://pepvault.app/research/semaglutide-friedrichsen-2021)
- [Liraglutide: 6.4% weight loss vs 15.8% on semaglutide in STEP 8](https://pepvault.app/research/liraglutide-step-8-2022)
- [Tirzepatide: 20.2% weight loss vs 13.7% on semaglutide at 72 weeks](https://pepvault.app/research/tirzepatide-surmount-5-2025)

### Brand against brand

- [Ozempic vs Wegovy](https://pepvault.app/drugs/compare/ozempic-vs-wegovy)
- [Wegovy vs Zepbound](https://pepvault.app/drugs/compare/wegovy-vs-zepbound)
- [Wegovy vs Mounjaro](https://pepvault.app/drugs/compare/wegovy-vs-mounjaro)
- [Wegovy vs Saxenda](https://pepvault.app/drugs/compare/wegovy-vs-saxenda)
- [Wegovy vs Foundayo](https://pepvault.app/drugs/compare/wegovy-vs-foundayo)

### Compound against compound

- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)
- [Semaglutide vs Semaglutide (oral)](https://pepvault.app/peptides/compare/semaglutide-vs-semaglutide-oral)
- [CagriSema vs Semaglutide](https://pepvault.app/peptides/compare/cagrisema-vs-semaglutide)
- [5-Amino-1MQ vs Semaglutide](https://pepvault.app/peptides/compare/5-amino-1mq-vs-semaglutide)
- [Semaglutide vs BPC-157](https://pepvault.app/peptides/compare/semaglutide-vs-bpc-157)
- [Semaglutide vs Exenatide](https://pepvault.app/peptides/compare/semaglutide-vs-exenatide)
- [Semaglutide vs Amycretin](https://pepvault.app/peptides/compare/semaglutide-vs-amycretin)
- [Semaglutide vs Petrelintide](https://pepvault.app/peptides/compare/semaglutide-vs-petrelintide)
- [Semaglutide vs Ecnoglutide](https://pepvault.app/peptides/compare/semaglutide-vs-ecnoglutide)
- [Semaglutide vs Efinopegdutide](https://pepvault.app/peptides/compare/semaglutide-vs-efinopegdutide)
- [Orforglipron vs Semaglutide (oral)](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide-oral)

## Questions about Wegovy

### What is the Wegovy dosing schedule?

The label raises the weekly injection every 4 weeks: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, then 2.4 mg from week 17. The tablets go 1.5 mg, 4 mg and 9 mg a month each, then 25 mg a day. A prescriber sets the actual schedule.

### What is the highest dose of Wegovy?

The label’s maximum for adults is 7.2 mg once a week (Wegovy HD), for those who tolerate 2.4 mg for at least 4 weeks. The tablets’ lasting dose is 25 mg a day.

### What if I miss a Wegovy injection?

If the next dose is more than 2 days away, the label says to take it as soon as possible; if it is less than 2 days away, skip it. After 2 or more missed weeks in a row, the climb restarts at a lower dose.

### Is there a Wegovy pill?

Yes. Wegovy tablets are approved for adults to reduce weight and to lower heart risk, starting at 1.5 mg a day and reaching 25 mg a day from day 91.

### How long can Wegovy stay out of the fridge?

A single-dose pen or syringe can be kept at 46°F to 86°F for up to 28 days before its cap comes off. A FlexTouch pen in use keeps for 56 days.

## Sources

- [WEGOVY (semaglutide) injection, for subcutaneous use, and WEGOVY (semaglutide) tablets, for oral use, FDA label on DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b) (version 19, published Jun 30, 2026; read Nov 18, 2026)
- [Drugs@FDA, NDA 215256](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256) (Wegovy, the injection; application first approved 2021)
- [Drugs@FDA, NDA 218316](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218316) (Wegovy, the tablets; application first approved 2025)

PepVault is not affiliated with Novo Nordisk. Wegovy is a trademark of its owner.

<!--promo-->

PepVault for iPhone

## Keep your own record in PepVault

Log each dose on your schedule, with a reminder for the next one.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=brand-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Keep your own record in PepVault

Log each dose on your schedule, with a reminder for the next one.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=brand-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## More on semaglutide

### Semaglutide on PepVault

- [Semaglutide in the peptide library](https://pepvault.app/peptides/semaglutide)
- [Semaglutide (oral) in the peptide library](https://pepvault.app/peptides/semaglutide-oral)
- [Semaglutide: half-life](https://pepvault.app/peptides/semaglutide/half-life)
- [Semaglutide: side effects](https://pepvault.app/peptides/semaglutide/side-effects)
- [Semaglutide: how long it takes to work](https://pepvault.app/peptides/semaglutide/how-long-to-work)
- [Semaglutide (oral): half-life](https://pepvault.app/peptides/semaglutide-oral/half-life)
- [Semaglutide (oral): side effects](https://pepvault.app/peptides/semaglutide-oral/side-effects)
- [Is Semaglutide legal? FDA, DEA and WADA status](https://pepvault.app/peptides/semaglutide/legal-status)
- [Is Semaglutide (oral) legal? FDA, DEA and WADA status](https://pepvault.app/peptides/semaglutide-oral/legal-status)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)
- [Semaglutide (oral) dose guide](https://pepvault.app/lab/dosage/semaglutide-oral)

### Free tools

- [GLP-1 titration calculator](https://pepvault.app/tools/glp1-titration-calculator)
- [Missed a GLP-1 dose?](https://pepvault.app/tools/missed-glp1-dose)
- [Peptide half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### The trials, in plain English

- [Semaglutide: 14.9% weight loss at 68 weeks in STEP 1](https://pepvault.app/research/semaglutide-step-1-2021)
- [Semaglutide STEP 4: -7.9% weight vs +6.9% after switch to placebo](https://pepvault.app/research/semaglutide-step-4-2021)
- [Semaglutide: 6.5% vs 8.0% had a major heart event in SELECT](https://pepvault.app/research/semaglutide-select-2023)
- [Semaglutide 7.2 mg: 18.7% weight loss at 72 weeks in STEP UP](https://pepvault.app/research/semaglutide-step-up-2025)
- [Semaglutide: MASH resolved in 62.9% vs 34.3% on placebo at 72 weeks](https://pepvault.app/research/semaglutide-sanyal-2025)
- [Semaglutide 25 mg pill: 13.6% weight loss at 64 weeks in OASIS 4](https://pepvault.app/research/semaglutide-oasis-4-2025)
- [Semaglutide: 35% lower lunch energy intake vs placebo at 20 weeks](https://pepvault.app/research/semaglutide-friedrichsen-2021)
- [Liraglutide: 6.4% weight loss vs 15.8% on semaglutide in STEP 8](https://pepvault.app/research/liraglutide-step-8-2022)
- [Tirzepatide: 20.2% weight loss vs 13.7% on semaglutide at 72 weeks](https://pepvault.app/research/tirzepatide-surmount-5-2025)

<!--promo-->

PepVault for iPhone

## Keep your own record in PepVault

Log each dose on your schedule, with a reminder for the next one.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=brand-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## Brand-name drugs

- [Every brand, by ingredient](https://pepvault.app/drugs)
- [Ozempic](https://pepvault.app/drugs/ozempic)
- [Rybelsus](https://pepvault.app/drugs/rybelsus)
- [Ozempic vs Wegovy](https://pepvault.app/drugs/compare/ozempic-vs-wegovy)
- [Wegovy vs Zepbound](https://pepvault.app/drugs/compare/wegovy-vs-zepbound)
- [Wegovy vs Mounjaro](https://pepvault.app/drugs/compare/wegovy-vs-mounjaro)

## The library

- [Semaglutide in the peptide library](https://pepvault.app/peptides/semaglutide)
- [Semaglutide (oral) in the peptide library](https://pepvault.app/peptides/semaglutide-oral)
- [The peptide reference library](https://pepvault.app/peptides)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it. PepVault is not affiliated with Novo Nordisk. Wegovy is a trademark of its owner.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
